Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Xencor Inc (XNCR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: XNCR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $28.2
1 Year Target Price $28.2
| 8 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -13.51% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 579.33M USD | Price to earnings Ratio - | 1Y Target Price 28.2 |
Price to earnings Ratio - | 1Y Target Price 28.2 | ||
Volume (30-day avg) 12 | Beta 0.87 | 52 Weeks Range 7.16 - 27.24 | Updated Date 06/30/2025 |
52 Weeks Range 7.16 - 27.24 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.94 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -163.17% | Operating Margin (TTM) -131.93% |
Management Effectiveness
Return on Assets (TTM) -11.42% | Return on Equity (TTM) -34.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 157660126 | Price to Sales(TTM) 4.55 |
Enterprise Value 157660126 | Price to Sales(TTM) 4.55 | ||
Enterprise Value to Revenue 1.24 | Enterprise Value to EBITDA -17.27 | Shares Outstanding 71170800 | Shares Floating 64282137 |
Shares Outstanding 71170800 | Shares Floating 64282137 | ||
Percent Insiders 1.23 | Percent Institutions 111.89 |
Analyst Ratings
Rating 4 | Target Price 28.2 | Buy 3 | Strong Buy 8 |
Buy 3 | Strong Buy 8 | ||
Hold - | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Xencor Inc
Company Overview
History and Background
Xencor, Inc. was founded in 1997. The company focuses on engineering antibodies and other protein therapies to treat diseases with unmet medical needs. It leverages its XmAb technology platform to create novel biologics.
Core Business Areas
- Biopharmaceutical Research and Development: Xencor focuses on discovering, developing, and commercializing engineered monoclonal antibodies and other protein therapeutics to treat a wide range of diseases with significant unmet medical needs. This includes oncology and autoimmune diseases.
- Technology Platform Licensing: Xencor's XmAb technology is licensed to other biopharmaceutical companies for their own drug development programs, generating revenue through royalties and upfront payments.
Leadership and Structure
Xencor is led by a management team with expertise in antibody engineering and drug development. The organizational structure includes research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- Monjuvi (tafasitamab-cxix): Monjuvi, co-marketed with MorphoSys, is an Fc-engineered antibody targeting CD19 approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Competitors include CAR-T therapies and other lymphoma treatments. Revenue for Xencor is based on royalties from MorphoSys's sales. No direct market share for Xencor.
- Vimdisertib: Vimdisertib, Xencor's internally developed inhibitor of MK2, is in Phase 1 clinical trials and is being evaluated in select patients with cancer, particularly in combination with chemotherapy. Competitors include other cancer therapies. Revenue: N/A - Currently in development.
- XmAbu00ae bispecific antibodies: Xencor's bispecific antibodies target multiple immune checkpoints and are in clinical trials for cancer and autoimmune diseases. Competitors: Other bispecific antibodies from companies like Regeneron (REGN) and Amgen (AMGN). Revenue: N/A - Currently in development.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, rapid technological advancements, and high regulatory hurdles. The market for antibody-based therapies is growing rapidly, driven by increasing prevalence of cancer, autoimmune diseases, and infectious diseases.
Positioning
Xencor is positioned as an innovator in antibody engineering. Its XmAb technology provides a competitive advantage by improving antibody potency, half-life, and effector function. It operates in a niche of developing differentiated antibody therapeutics.
Total Addressable Market (TAM)
The total addressable market for antibody therapeutics is estimated to be in the hundreds of billions of dollars annually. Xencor is positioned to capture a portion of this market through its proprietary XmAb technology and pipeline of novel biologics.
Upturn SWOT Analysis
Strengths
- Proprietary XmAb technology platform
- Strong pipeline of novel antibody therapeutics
- Partnerships with major pharmaceutical companies
- Experienced management team
- Proven ability to engineer differentiated antibodies
Weaknesses
- Reliance on partnerships for commercialization
- Clinical trial risks associated with drug development
- Competition from larger pharmaceutical companies
- Limited internal manufacturing capacity
- Dependence on key personnel and technologies
Opportunities
- Expansion of the pipeline through internal research and development
- Strategic acquisitions or in-licensing of complementary technologies
- Commercialization of internal assets
- Expansion into new therapeutic areas
- Increased adoption of XmAb technology by other companies
Threats
- Failure of clinical trials
- Regulatory hurdles and delays
- Competition from biosimilars
- Patent challenges
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- REGN
- AMGN
- MRTX
- BMY
Competitive Landscape
Xencor's XmAb platform provides a competitive advantage in engineering differentiated antibodies. However, it faces competition from larger pharmaceutical companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Growth is driven by pipeline advancements and milestone payments from partnerships.
Future Projections: Analyst projections would vary and can be found on financial websites. Consensus estimates point towards continued revenue growth and eventual profitability.
Recent Initiatives: Focus on advancing pipeline candidates, expanding partnerships, and exploring new therapeutic areas.
Summary
Xencor is a biotechnology company with a promising antibody engineering platform. Its partnerships provide revenue and validation, but clinical trial risks and competition remain significant challenges. Advancing its internal pipeline and expanding partnerships are key to future growth. The company's financial performance is improving, but achieving sustained profitability is critical.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Market share data is approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Xencor Inc
Exchange NASDAQ | Headquaters Pasadena, CA, United States | ||
IPO Launch date 2013-12-03 | Co-Founder, CEO, President & Director Dr. Bassil I. Dahiyat Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 250 | Website https://www.xencor.com |
Full time employees 250 | Website https://www.xencor.com | ||
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.